AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02762240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DHQP 2016
Description: DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
Study NCT02762240 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DHQP 2018
Description: DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
Study NCT00801034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium
Description: tablets, 1 tablet 2 times per day in 28 days
Study NCT00801034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Potassium
Description: Tablets, 5 tablets 2 times per day for 28 days
Study NCT03860012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: Patients on daily folic acid with a normal baseline folate level will be switched to once weekly dosing.
Study NCT03702946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxytocin in abdominal myomectomy
Description: Women were divided into two groups randomly. In the study group 30 Units of oxytocin in 1000 ml normal saline were given during surgery, at the rate of 15units/hour. In control group, pure normal saline was given
Study NCT04937621 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ECG data analysis
Description: Baseline ECG as well as follow-up ECG are analysed
Study NCT04937621 — intervention group
Intervention type: DRUG
Intervention: Treatment data collect
Description: Baseline treatment data as well as follow-up treatment data are collected
Study NCT02476084 — intervention group
Intervention type: OTHER
Intervention: Musculoskeletal Ultrasound Imaging
Description: B-mode and PD musculoskeletal ultrasound examination of selected joints.
Study NCT02476084 — intervention group
Intervention type: OTHER
Intervention: Synovial biopsy
Description: US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
Study NCT02476084 — intervention group
Intervention type: OTHER
Intervention: Biological samples collection
Description: Draw of research blood samples.
Study NCT02476084 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Administration of validated patients' questionnaires.
Study NCT01447485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan (VAL489)
Study NCT03785860 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Fiber
Description: Dietary fiber will be given in a powder form to mix with a beverage of one's choice.
Study NCT03785860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given in a powder form to mix with a beverage of one's choice.
Study NCT04850976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Every eligible patient was intubated using either SAM-VL or McGrath MAC® according to their randomization allocation
Study NCT04850976 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Description: Every eligible patient was intubated using either SAM-VL or McGrath MAC® according to their randomization allocation
Study NCT00191724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin Alfa (Activated)
Description: 6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
Study NCT00191724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
Study NCT06698432 — intervention group
Intervention type: DEVICE
Intervention: caIMR
Description: Coronary angiography-derived IMR (caIMR) is a novel and accurate alternative that can enable the assessment of coronary microvascular function easier, and more efficiently and does not require pressure wire or adenosine.
Study NCT04937621 — intervention group
Intervention type: BIOLOGICAL
Intervention: Biological check-up data collect
Description: Baseline Biological check-up data as well as follow-up data are collected
Study NCT04937621 — intervention group
Intervention type: OTHER
Intervention: Collection of clinical events of interest
Description: Clinical events of interest at the baseline as well as follow-up clinical events are collected
Study NCT04049968 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile health application (APP)
Description: The mobile health application (APP) was applied to patients with oral cancer.
Study NCT04049968 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine health care and instruction
Description: Traditional routine health care and instruction was applied to patients with oral cancer.
Study NCT01431560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of the ankle fracture (Solco )
Description: fixation with metallic implant
Study NCT01431560 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of the ankle fracture (Freedom)
Description: fixation with biodegradable implant
Study NCT01324336 — intervention group
Intervention type: DRUG
Intervention: 6-Mercaptopurine
Description: 75 mg/m2/dose/day
Study NCT04057391 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: QT Scanner
Description: Diagnostic test that is repeatable, non-invasive imaging tool for the early and accurate detection of breast cancer, breast abnormalities, and musculoskeletal findings. Comparing with mammography, the QT Scanner uses harmless soundwaves to screen and diagnose the breast.
Study NCT01426880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC, 2 min/mL weekly, infusion
Study NCT01426880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: background treatment
Description: background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients).
Study NCT01426880 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: background treatment
Description: background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.~Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients).
Study NCT02086994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: misoprostol
Description: given after the delivery of the anterior shoulder of the baby.
Study NCT02086994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbetocin
Description: given after delivery of anterior shoulder
Study NCT03758144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin 200 MG
Description: patients with type 2 diabetes and gut dysbiosis will be given rifaximin
Study NCT02405845 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Computed Tomographic Angiogram
Description: 1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
Study NCT00814528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-ALA plus Blu-Light
Description: 20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
Study NCT00814528 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, Imiquimod or treatment with cryotherapy
Description: Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
Study NCT03958955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Delgocitinib cream
Description: Cream for topical application.
Study NCT03958955 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Delgocitinib cream vehicle
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study NCT01453712 — intervention group
Intervention type: RADIATION
Group type: NO_INTERVENTION
Intervention: Control group
Description: Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
Study NCT01453712 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
Study NCT03280420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early catheter removal
Description: Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy.
Study NCT03280420 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late catheter removal
Description: Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.~After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy.
Study NCT00390858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
Study NCT03325361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tube drain insertion
Description: A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
Study NCT00142584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol (NEB)
Description: Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
Study NCT00142584 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol (MET)
Description: Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
Study NCT03664557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ER Reboa TM Catheter
Description: During cardiac arrest occlusion of descending aorta to redistribute CPR-generated blood flow to brain and coronaries
Study NCT03435744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg
Description: Simvastatin 20 mg added to TAU for 3 months.
Study NCT03435744 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Matched placebo added to TAU for 3 months
Study NCT04387851 — intervention group
Intervention type: BEHAVIORAL
Intervention: Placebo induction
Description: The placebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce placebo effects on somatosensory sensations.
Study NCT04387851 — intervention group
Intervention type: BEHAVIORAL
Intervention: Control
Description: Placebo and nocebo effects should be measured relative to a control group (between-subjects design). In the case of within-subjects designs, these will be included to the extent possible (in a separate analysis or descriptively depending on the number of results).
Study NCT04387851 — intervention group
Intervention type: BEHAVIORAL
Intervention: Nocebo
Description: The nocebo interventions of interest are experimental learning methods (e.g. verbal suggestion, conditioning), used to induce nocebo effects on somatosensory sensations.
Study NCT02309489 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner involvement
Description: Partner is involved in maternity care
Study NCT01830699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept
Description: 160 mg intra-bursal once
Study NCT01830699 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corticosteroid
Description: 2 cc (40 mg/mL) triamcinolone intra-bursal once
Study NCT01986985 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET/MRI system
Description: Compared to PET CT
Study NCT01862198 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided biliary drainage with a hybrid metallic stent
Description: EUS-guided biliary drainage with a newly designed hybrid metallic stent
Study NCT01122706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taiji training
Description: Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
Study NCT02953054 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DMTS
Description: DMTS applied before surgery and worn for 72 hours
Study NCT02953054 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching patches that have no active drug applied before surgery and worn for 72 hours.
Study NCT02734238 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sesame Oil
Description: 200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
Study NCT02734238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone enanthate
Description: 200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
Study NCT01845350 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: M2 macrophage introduction
Description: * Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients~* Intrathecal introduction of autologous M2 macrophages
Study NCT01639651 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posterior capsule stretching
Description: Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
Study NCT01639651 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobilization with movement
Description: Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
Study NCT02821481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-alanine
Study NCT02821481 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00191724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Enoxaparin
Description: 1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
Study NCT00191724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenous (IV), one infusion, over 12 hours
Study NCT00191724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin Alfa (Activated)
Description: 12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
Study NCT00191724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin Alfa (Activated)
Description: 18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
Study NCT00191724 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin Alfa (Activated)
Description: 24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
Study NCT04378829 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
Description: Platelet count, platelet, mean platelet volume and platelet distribution Width in COVID-19
Study NCT03232814 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group-based walking
Description: The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
Study NCT02430948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Color-coded materials
Description: A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
Study NCT02430948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Academic detailing
Description: Educational outreach to address the rationale and data supporting recommendations for and against screening
Study NCT02430948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard support
Description: Screening recommendations presented in standard format
Study NCT02430948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard support
Description: Screening recommendations presented in standard format
Study NCT02430948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No academic detailing
Description: Physician receives study orientation for not the academic detailing curriculum
Study NCT02430948 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No academic detailing
Description: Physician receives study orientation for not the academic detailing curriculum
Study NCT02637505 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic microfracture (MF)
Description: Arthroscopy With microfracture procedure
Study NCT02669173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
Study NCT02669173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
Study NCT03065049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Facilitated Counseling
Description: Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
Study NCT03065049 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit activity tracker
Description: Participants will be given a Fitbit activity tracker to monitor physical activity.
Study NCT03065049 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit activity tracker
Description: Participants will be given a Fitbit activity tracker to monitor physical activity.